Literature DB >> 24556721

RNA editome imbalance in hepatocellular carcinoma.

Lihua Qi1, Tim Hon Man Chan, Daniel G Tenen, Leilei Chen.   

Abstract

Adenosine-to-inosine conversion (A-to-I editing), a posttranscriptional modification on RNA, contributes to extensive transcriptome diversity. A-to-I editing is a hydrolytic deamination process, catalyzed by adenosine deAminase acting on double-stranded RNA (ADAR) family of enzymes. ADARs are essential for normal mammalian development, and disturbance in RNA editing has been implicated in various pathologic disorders, including cancer. Thanks to next-generation sequencing, rich databases of transcriptome evolution for cancer development at the resolution of single nucleotide have been generated. Extensive bioinformatic analysis revealed a complex picture of RNA editing change during transformation. Cancer displayed global hypoediting of Alu-repetitive elements with gene-specific editing pattern. In particular, hepatocellular carcinoma editome is severely disrupted and characterized by hyper- and hypoediting of different genes, such as hyperedited AZIN1 (antizyme inhibitor 1) and FLNB (filamin B, β) and hypoedited COPA (coatomer protein complex, subunit α). In hepatocellular carcinoma, not only the recoding editing in exons, but also the editing in noncoding regions (e.g., Alu-repetitive elements and microRNA) displays such complex editing pattern with site-specific editing trend. In this review, we will discuss current research progress on the involvement of abnormal A-to-I editing in cancer development, more specifically on hepatocellular carcinoma. ©2014 AACR

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24556721     DOI: 10.1158/0008-5472.CAN-13-3485

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Comparison of RNA Editing Activity of APOBEC1-A1CF and APOBEC1-RBM47 Complexes Reconstituted in HEK293T Cells.

Authors:  Aaron D Wolfe; Don B Arnold; Xiaojiang S Chen
Journal:  J Mol Biol       Date:  2019-03-04       Impact factor: 5.469

2.  AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer.

Authors:  Kunitoshi Shigeyasu; Yoshinaga Okugawa; Shusuke Toden; Jinsei Miyoshi; Yuji Toiyama; Takeshi Nagasaka; Naoki Takahashi; Masato Kusunoki; Tetsuji Takayama; Yasuhide Yamada; Toshiyoshi Fujiwara; Leilei Chen; Ajay Goel
Journal:  JCI Insight       Date:  2018-06-21

3.  Hyper-Editing of Cell-Cycle Regulatory and Tumor Suppressor RNA Promotes Malignant Progenitor Propagation.

Authors:  Qingfei Jiang; Jane Isquith; Maria Anna Zipeto; Raymond H Diep; Jessica Pham; Nathan Delos Santos; Eduardo Reynoso; Julisia Chau; Heather Leu; Elisa Lazzari; Etienne Melese; Wenxue Ma; Rongxin Fang; Mark Minden; Sheldon Morris; Bing Ren; Gabriel Pineda; Frida Holm; Catriona Jamieson
Journal:  Cancer Cell       Date:  2019-01-03       Impact factor: 31.743

Review 4.  RNA editing-dependent epitranscriptome diversity in cancer stem cells.

Authors:  Qingfei Jiang; Leslie A Crews; Frida Holm; Catriona H M Jamieson
Journal:  Nat Rev Cancer       Date:  2017-04-18       Impact factor: 60.716

5.  ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis.

Authors:  Maria Anna Zipeto; Angela C Court; Anil Sadarangani; Nathaniel P Delos Santos; Larisa Balaian; Hye-Jung Chun; Gabriel Pineda; Sheldon R Morris; Cayla N Mason; Ifat Geron; Christian Barrett; Daniel J Goff; Russell Wall; Maurizio Pellecchia; Mark Minden; Kelly A Frazer; Marco A Marra; Leslie A Crews; Qingfei Jiang; Catriona H M Jamieson
Journal:  Cell Stem Cell       Date:  2016-06-09       Impact factor: 24.633

6.  Precancer Atlas to Drive Precision Prevention Trials.

Authors:  Avrum Spira; Matthew B Yurgelun; Ludmil Alexandrov; Anjana Rao; Rafael Bejar; Kornelia Polyak; Marios Giannakis; Ali Shilatifard; Olivera J Finn; Madhav Dhodapkar; Neil E Kay; Esteban Braggio; Eduardo Vilar; Sarah A Mazzilli; Timothy R Rebbeck; Judy E Garber; Victor E Velculescu; Mary L Disis; Douglas C Wallace; Scott M Lippman
Journal:  Cancer Res       Date:  2017-04-01       Impact factor: 13.312

7.  Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73).

Authors:  Natasha T Snider; Peter J Altshuler; Shanshan Wan; Theodore H Welling; James Cavalcoli; M Bishr Omary
Journal:  Mol Biol Cell       Date:  2014-10-08       Impact factor: 4.138

8.  Circular RNA expression is suppressed by androgen receptor (AR)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma.

Authors:  Liang Shi; Peijian Yan; Yuelong Liang; Yin Sun; Jiliang Shen; Senjun Zhou; Hui Lin; Xiao Liang; Xiujun Cai
Journal:  Cell Death Dis       Date:  2017-11-16       Impact factor: 8.469

9.  Genetic Determinants of RNA Editing Levels of ADAR Targets in Drosophila melanogaster.

Authors:  Yerbol Z Kurmangaliyev; Sammi Ali; Sergey V Nuzhdin
Journal:  G3 (Bethesda)       Date:  2015-12-12       Impact factor: 3.154

10.  An RNA editing/dsRNA binding-independent gene regulatory mechanism of ADARs and its clinical implication in cancer.

Authors:  Lihua Qi; Yangyang Song; Tim Hon Man Chan; Henry Yang; Chi Ho Lin; Daryl Jin Tai Tay; HuiQi Hong; Sze Jing Tang; Kar Tong Tan; Xi Xiao Huang; Jaymie Siqi Lin; Vanessa Hui En Ng; Julien Jean Pierre Maury; Daniel G Tenen; Leilei Chen
Journal:  Nucleic Acids Res       Date:  2017-10-13       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.